News

• Prodotti competitors 11 ottobre 2024

  Lancet: Dynamic choice HIV prevention with cabotegravir long-acting injectable in rural Uganda and Kenya: a randomised trial extension

• Prodotti GS / Area HIV 15 luglio 2024

  Lancet: HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial

• Prodotti competitors / Area HIV Prodotti GS / Area HIV 2 luglio 2024

  Lancet: Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial

• Prodotti competitors / Area HIV 29 maggio 2024

  Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial

• Prodotti competitors / Area HIV 22 maggio 2024

  Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phas

• Prodotti GS / Area Oncology 21 maggio 2024

  Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial

• Prodotti competitors / Area Oncology 6 maggio 2024

  Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study

• Autorità nazionali / Area Oncology 6 maggio 2024

  Sviluppo scientifico dei dati dei registri di monitoraggio AIFA (1)

• Prodotti competitors / Area Oncology 26 aprile 2024

  Takeda receives positive CHMP Opinion for Fruquintinib in previously treated Metastatic Colorectal Cancer

• Prodotti competitors / Area Oncology 15 dicembre 2023

  Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study